Pharmaceutical firm Suven Life Sciences today said the European Patent Office (EPO) has issued three patents to its chemical entities, which are used in treating nerve disorders.
"The company gets three patents -- EP1537113, EP1704154 and EP1856132 and the said are valid until 23, and 24, 2022, respectively," Suven said in a filing to the Bombay Stock Exchange.
The granted claims of the patents includes therapeutic agents, useful in the treatment of neurodegenerative disorders like Alzheimer’s, Parkinson's, and schizophrenia, the filing added.
"We are very pleased by the grant of these patents to Suven by EPO for our pipeline of molecules in central nervous system arena that are being developed for cognitive disorders," Suven CEO Venkat Jasti said.
With these new patents, Suven has total of seven granted EPO patents on new chemical entities.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app